ArticleHuman genomics2026
Deciphering the role of cell-free extrachromosomal circular DNA in human heart failure.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundExtrachromosomal circular DNAs (eccDNAs) are well-established drivers of tumorigenesis, yet their landscape and functional significance in human heart failure (HF) remain largely unknown.
methodsUsing Tn5 transposase-based sequencing, we comprehensively profiled plasma eccDNAs from healthy controls and HF patients with myocardial ischemia (MI-HF) or non-myocardial ischemia (NMI-HF). Bioinformatics was employed to probe their chromosomal origins, genomic features, and potential roles in the development of HF. Circular structures of candidate eccDNAs were validated by inward and outward PCR followed by Sanger sequencing. Their clinical prognostic value was assessed by Kaplan-Meier and Cox regression analyses in a patient cohort.
resultsMost plasma eccDNAs were shorter than 1 kb and originated from all chromosomes, with selective enrichment from specific genomic regions including 5' UTRs, CpG islands, and Alu elements. Characteristic nucleotide repeats were identified at eccDNA junction sites. The circular structure of eccDNAs was confirmed. Furthermore, we discovered that the eccDNA ENPP1
conclusionsThis study delineates the first detailed landscape of plasma eccDNAs in HF and reveals their potential as noninvasive biomarkers for risk stratification. Our findings lay a crucial foundation for future research into eccDNA biology and their translational applications in cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.